Laut einer neuen Studie mit über 3 Millionen Erwachsenen, die in England im Herbst 2022 geimpft wurden, verringerten Auffrischungsimpfungen das Risiko von Krankenhausaufenthalten und Todesfällen im Zusammenhang mit COVID-19. Dies ist ein weiterer Beweis für die Wirksamkeit der Auffrischungsimpfung gegen COVID-19.
https://www.bristol.ac.uk/news/2026/february/booster-jabs-reduce-the-risks-of-covid-19-deaths.html
3 Kommentare
Booster jabs reduce the risks of COVID-19 deaths, study finds
Booster vaccines reduced the risk of COVID 19–related hospitalisation and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research led by the universities of Bristol and Oxford, provides further evidence of the effectiveness of booster vaccination against COVID-19.
For those interested, here’s the link to the peer reviewed journal article:
https://www.sciencedirect.com/science/article/pii/S0264410X26000848
If you totally ignore Long COVID, persistence, and other long-term risks that this isn’t preventing, then it looks like it’s great.
This really comes down to the use of efficacy; if you set low parameters, you can claim that something has high efficacy because it’s based on the metrics you create in your study.
This is a very poor level of protection against a virus as dangerous as SARS-CoV-2.
And don’t come at me, because I already got a better COVID vaccine approved, but its uptake is so low that it’s not included in these studies.
It provides 100% protection against hospitalization (according to US standards; in other countries with centralized medicine, patients are hospitalized earlier), and it blocks infection 70-80% of the time.
But yall are trying real hard to make this square peg fit in a round hole.
For context, the study was for people over the age of 50 and measured risk of hospitalization and death for 1 year after getting the booster. Over that time, it cut the risk of hospitalization and death in half.
Those are solid numbers, but that is also the most cherry picked group/length to observe efficacy. I wonder what the efficacy looks like for the 18-45 crowd and for everyone beyond 1 year.